After applying false discovery rate (FDR) correction (FDR < 0.05), three metabolites—myristoleate (14:1n5), tricosanoyl sphingomyelin (d18:1/23:0), and 5α-androstan-3β, 17β-diol monosulfate (2)—remained significantly associated with an increased risk of ER+ breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.